8-K: Y-mAbs Therapeutics Announces CFO Departure and Consulting Agreement

Y-mAbs Therapeutics has announced the departure of its CFO, Bo Kruse, effective July 31, 2024, and a subsequent consulting agreement with Mr. Kruse's firm.

Summary

• Y-mAbs Therapeutics, Inc. has entered into a separation agreement with its former CFO, Bo Kruse, who will depart on July 31, 2024.
• Mr. Kruse will receive his base salary up to July 31, 2024, a pro-rated 2024 bonus of $151,376, and continued vesting of certain equity awards.
• Concurrently, Y-mAbs has engaged Investeringsselskabet GH ApS, Mr. Kruse's private company, for consulting services starting August 1, 2024.
• The consulting agreement is for one year, with a monthly fee of $43,251 for Mr. Kruse's services related to financial operations and corporate governance.
• The separation agreement includes confidentiality and non-disparagement clauses, as well as a mutual release of claims.

Sentiment

Score: 6

Explanation: The news is neutral to slightly negative due to the CFO's departure, but the consulting agreement provides some reassurance. The company is managing the transition in a structured way.

Positives

• The company has secured ongoing access to Mr. Kruse's expertise through a consulting agreement, ensuring a smooth transition.
• The separation agreement includes a mutual release of claims, reducing potential legal risks.
• The consulting agreement provides a clear framework for Mr. Kruse's continued involvement with the company.

Negatives

• The departure of the CFO could create a period of uncertainty for the company's financial operations.
• The company will incur additional costs for both the separation package and the consulting agreement.

Risks

• The transition to a new CFO could pose challenges to the company's financial management.
• There is a risk that the consulting arrangement may not fully replace the expertise of a full-time CFO.
• The company may face challenges in finding a suitable replacement for the CFO position.

Future Outlook

The company has secured a consulting agreement with the former CFO to ensure continuity during the transition period, and is actively recruiting a new CFO.

Management Comments

• The company has initiated the process of recruiting a new employee to take over the position as CFO.
• The company will see to that all statements, if any (internal as well as external), informing of termination of the employment are announced/published.

Industry Context

Executive transitions are common in the biopharmaceutical industry, and companies often use consulting agreements to maintain expertise during these periods. This move is not unusual for a company of this size and stage.

Comparison to Industry Standards

• The use of a consulting agreement with a departing executive is a common practice in the biopharmaceutical industry to ensure a smooth transition and maintain institutional knowledge, similar to moves made by companies like Amgen and Gilead Sciences during executive changes.
• The severance package, including pro-rated bonus and continued vesting of equity, is generally in line with industry standards for executive departures, comparable to packages offered by companies such as Regeneron and Biogen.
• The monthly consulting fee of $43,251 is within the typical range for experienced financial consultants in the biotech sector, similar to rates charged by consultants working with companies like Vertex Pharmaceuticals and Incyte.

Management Changes

Related Party Transactions

• The consultancy agreement with Investeringsselskabet GH ApS, a company owned by the former CFO, is a related party transaction.

Stakeholder Impact

• Shareholders may experience short-term uncertainty due to the CFO's departure.
• Employees may experience some disruption during the transition period.
• The company's creditors and suppliers are unlikely to be significantly impacted by this change.

Next Steps

• The company will onboard a new CFO.
• The company will continue to utilize Mr. Kruse's consulting services for financial operations and corporate governance.
• The company will ensure a smooth transition of responsibilities from the former CFO to the new CFO.

Key Dates

Keywords

CFO, separation agreement, consulting agreement, financial operations, corporate governance, executive departure, Bo Kruse, Y-mAbs Therapeutics